CN103265482A - Preparation method of bosutinib - Google Patents
Preparation method of bosutinib Download PDFInfo
- Publication number
- CN103265482A CN103265482A CN 201310236253 CN201310236253A CN103265482A CN 103265482 A CN103265482 A CN 103265482A CN 201310236253 CN201310236253 CN 201310236253 CN 201310236253 A CN201310236253 A CN 201310236253A CN 103265482 A CN103265482 A CN 103265482A
- Authority
- CN
- China
- Prior art keywords
- preparation
- bosutinib
- reaction
- methoxyl group
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 239000002145 L01XE14 - Bosutinib Substances 0.000 title claims abstract description 30
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229960003736 bosutinib Drugs 0.000 title claims abstract description 29
- 230000005494 condensation Effects 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000006482 condensation reaction Methods 0.000 claims abstract description 11
- 238000006722 reduction reaction Methods 0.000 claims abstract description 5
- 238000006243 chemical reaction Methods 0.000 claims description 23
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 22
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 claims description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- FPQKZTTXKWGJRN-UHFFFAOYSA-N 2-chloro-5-methoxybenzaldehyde Chemical class COC1=CC=C(Cl)C(C=O)=C1 FPQKZTTXKWGJRN-UHFFFAOYSA-N 0.000 claims description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 10
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 9
- 238000007363 ring formation reaction Methods 0.000 claims description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical group [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 8
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 8
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 7
- 238000005660 chlorination reaction Methods 0.000 claims description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 239000012279 sodium borohydride Substances 0.000 claims description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 6
- -1 acetoxyl group Chemical group 0.000 claims description 5
- 210000005252 bulbus oculi Anatomy 0.000 claims description 5
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 5
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 claims description 5
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 4
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims description 4
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- GOPYZMJAIPBUGX-UHFFFAOYSA-N [O-2].[O-2].[Mn+4] Chemical class [O-2].[O-2].[Mn+4] GOPYZMJAIPBUGX-UHFFFAOYSA-N 0.000 claims description 3
- 229960004217 benzyl alcohol Drugs 0.000 claims description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 229910052763 palladium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- OXHNLMTVIGZXSG-UHFFFAOYSA-N 1-Methylpyrrole Chemical compound CN1C=CC=C1 OXHNLMTVIGZXSG-UHFFFAOYSA-N 0.000 claims description 2
- 229910015900 BF3 Inorganic materials 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 2
- RUYNUXHNGYKVTI-UHFFFAOYSA-L N1=CC=CC=C1.[Cr](=O)(=O)(O)O[Cr](=O)(=O)O.[Cl] Chemical compound N1=CC=CC=C1.[Cr](=O)(=O)(O)O[Cr](=O)(=O)O.[Cl] RUYNUXHNGYKVTI-UHFFFAOYSA-L 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000007809 chemical reaction catalyst Substances 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- 238000005984 hydrogenation reaction Methods 0.000 claims description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 2
- 229940055742 indium-111 Drugs 0.000 claims description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 2
- FIYYMXYOBLWYQO-UHFFFAOYSA-N ortho-iodylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I(=O)=O FIYYMXYOBLWYQO-UHFFFAOYSA-N 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- YHBDIEWMOMLKOO-UHFFFAOYSA-I pentachloroniobium Chemical compound Cl[Nb](Cl)(Cl)(Cl)Cl YHBDIEWMOMLKOO-UHFFFAOYSA-I 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229940086542 triethylamine Drugs 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 3
- DXKTXDIOPFHUEI-UHFFFAOYSA-N 2,4-dichloro-5-methoxybenzaldehyde Chemical compound COC1=CC(C=O)=C(Cl)C=C1Cl DXKTXDIOPFHUEI-UHFFFAOYSA-N 0.000 abstract 2
- WNVBTQRXFWJUAI-UHFFFAOYSA-N 4-amino-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile Chemical compound COC=1C=C2C(=C(C=NC2=CC1OCCCN1CCN(CC1)C)C#N)N WNVBTQRXFWJUAI-UHFFFAOYSA-N 0.000 abstract 2
- 238000009776 industrial production Methods 0.000 abstract 1
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- VNVGDKQKDQGFAR-UHFFFAOYSA-N 3-(chloromethoxy)aniline Chemical class NC1=CC=CC(OCCl)=C1 VNVGDKQKDQGFAR-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 238000010719 annulation reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- 150000002466 imines Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 125000002524 organometallic group Chemical group 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- YVLMARQGAFPBMI-UHFFFAOYSA-N CN1CCN(CCCOC(C(C2)O)=Cc(nc3)c2c(N)c3C#N)CC1 Chemical compound CN1CCN(CCCOC(C(C2)O)=Cc(nc3)c2c(N)c3C#N)CC1 YVLMARQGAFPBMI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940083476 bosulif Drugs 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000011968 lewis acid catalyst Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- REPVNSJSTLRQEQ-UHFFFAOYSA-N n,n-dimethylacetamide;n,n-dimethylformamide Chemical compound CN(C)C=O.CN(C)C(C)=O REPVNSJSTLRQEQ-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- GTDQGKWDWVUKTI-UHFFFAOYSA-N o-aminoacetophenone Chemical class CC(=O)C1=CC=CC=C1N GTDQGKWDWVUKTI-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000004214 philadelphia chromosome Anatomy 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The invention discloses a preparation method of bosutinib (I). The preparation method comprises the step that 6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-amino-3-quinolinecarbonitrile (II) and 2,4-dichloro-5-methoxybenzaldehyde (III) carry out condensation and reduction reactions to obtain bosutinib (I). The preparation method is easy in obtainment of raw materials, concise in process, economical and environment-friendly and suitable for industrial production.
Description
Technical field
The invention belongs to organic synthesis highway route design and bulk drug thereof and intermediate preparation technical field, particularly a kind of preparation method of bosutinib.
Background technology
Bosutinib (Bosutinib) is a kind of potent protein kinase (Src/Abl) inhibitor, can suppress the autonomous phosphorylation of Src albumen in the various human tumour cell, also can suppress the phosphorylation process of Src and Abl substrate.This medicine is developed by Hui Shi (Wyeth) drugmaker under the Pfizer (Pfizer), in on September 4th, 2012 in U.S.'s Initial Public Offering, be approved for the treatment of chronic myelocytic leukemia (CML) adult patients that chronic phase, acceleration period or acute transformation phase Philadelphia chromosome be positive, commodity are called Bosulif.
The chemistry of bosutinib is by name: 4-[(2,4-two chloro-5-p-methoxy-phenyls) amino]-6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-3-quinoline formonitrile HCN, its structural formula is:
Relevant bosutinib preparation method studies existing report, removes the method for transformation of side chain functionalities and transforms outside order updates, and mainly contains following several route of synthesis for the research of 3-quinoline formonitrile HCN parent nucleus Cheng Huan:
World patent WO2003/093241 number, WO2004/075898 number, WO2002/44166 number, United States Patent (USP) US99/0406573 number and Chinese patent CN101012225A etc. have reported that with anils (IV) be starting raw material, through carrying out condensation and cyclization with (Z)-3-oxyethyl group-2-itrile group-ethyl propenoate (Va) or ethoxy methylene diethyl malonate (Vb), make 4-oxo-3-quinoline 6-carbonitrile derivatives (VI), intermediate (VI) and phosphorus oxychloride, the chlorination of chlorizating agent such as phosphorus trichloride or thionyl chloride generates 4-chloro-3-quinoline 6-carbonitrile derivatives (VII), chloro intermediate (VII) and 2, the replacement of 4-two chloro-5-anisidines (VIII) prepares bosutinib (I).This synthetic route is the main stream approach for preparing bosutinib at present; characteristics with reaction classics and process stabilizing; but because cyclization needs high temperature and long-time the backflow; chlorination reaction need use phosphorus oxychloride or thionyl chloride etc. to influence the danger product of environment, has limited the industrialization prospect of this technology.
World patent has also been reported the similar preparation method of a kind of and above-mentioned technology for WO2003/093241 number, difference is that adjacent manthanoate anils (IX) is raw material, elder generation and DMF-DMA condensation generate intermediate (X), and intermediate (X) becomes ring to generate 4-chloro-3-quinoline 6-carbonitrile derivatives (VI) under the effect of organo-metallic lithium reagent.Because the reaction needed of organo-metallic lithium reagent is carried out under very low temperature (78 ℃), there is the use of dangerization product such as phosphorus oxychloride equally in follow-up chlorination, makes the more difficult industrialization of its preparation method.
World patent has been reported a kind of one-tenth ring method for WO2009/149622 number: be raw material with o-aminoacetophenone derivative (XI), replace (XIII) and the DMF-DMA cyclic condensation obtains 4-oxo-3-quinoline 6-carbonitrile derivatives (VI) through bromination (XII), itrile group.This method advantage is that raw material is easy to get, but step is more, can not avoid the use of dangerization product such as phosphorus oxychloride equally.
World patent has been reported the operational path of another kind of preparation bosutinib for WO2005/019201 number: with 2; 4-two chloro-5-anisidine (VIII) aniline are raw material; generate N-(2 with itrile group acetic acid acidylate; 4-two chloro-5-p-methoxy-phenyls)-2-itrile group ethanamide (IXV); intermediate (IXV) generates imines condenses (XV) with anils (IV) condensation; annulation taking place behind intermediate (XV) and the phosphorus oxychloride chloro again obtain the amino replacement-3-quinoline 6-carbonitrile derivatives (XVI) of 4-, (XVI) passes through side chain R again
1And R
2Functional group conversion make bosutinib (I).This synthetic route is that condensation and substitution reaction are united two into one, and has simplified reactions steps, but because the chlorination annulation must use chlorizating agents such as phosphorus oxychloride, still bigger for environmental influence.
What Chinese patent was reported for CN101792416A number is to generate imine derivative (XVII) by adjacent manthanoate anils (IX) and itrile group acetal generation condensation reaction, and intermediate (XVII) cyclization under alkaline condition generates 4-oxo-3-quinoline 6-carbonitrile derivatives (VI).This method technology is succinct, but raw material is difficult for acquisition, and danger product such as while phosphorus oxychloride still can't be avoided.
Summary of the invention
The objective of the invention is at defective of the prior art, provide a kind of and have that raw material is easy to get, technology is succinct and the preparation method of the bosutinib of environmental protection and economy.
For achieving the above object, the present invention has adopted following main technical schemes: the preparation method of a kind of bosutinib (I),
Its preparation process comprises: 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-amino-3-quinoline formonitrile HCN (II) and 2,4-two chloro-5-methoxybenzaldehydes (III) carry out condensation, reduction reaction obtains bosutinib (I).
In addition, the present invention also proposes following attached technical scheme:
The acid binding agent of described condensation reaction is salt of wormwood, saleratus, potassium hydroxide, yellow soda ash, sodium bicarbonate, sodium hydroxide, sodium methylate, potassium tert.-butoxide, triethylamine, diisopropylamine, pyridine, N-methylpyrrole, N-methyl piperidine or N-methylmorpholine, preferred triethylamine or pyridine.
The reductive agent of described reduction reaction is sodium borohydride, POTASSIUM BOROHYDRIDE, sodium cyanoborohydride, acetoxyl group sodium borohydride or catalytic hydrogenation reaction, preferred sodium borohydride or POTASSIUM BOROHYDRIDE.
Described catalytic hydrogenation reaction is normal pressure hydrogenation, and the catalyzer of its catalytic hydrogenation can be selected palladium charcoal, palladium calcium carbonate or Raney's nickel, preferred palladium calcium carbonate.
Described raw material 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-chemical structure of 4-amino-3-quinoline formonitrile HCN is suc as formula shown in (II),
Its preparation process comprises: 3-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-anisidine (IIa), triethyl orthoformate (IIb) and the third two eyeballs (IIc) carry out the condensation and cyclization reaction and make 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-amino-3-quinoline formonitrile HCN (II).
The feed ratio of described condensation and cyclization reaction is 3-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-anisidine (IIa): triethyl orthoformate (IIb): the third two eyeballs (IIc) are 1: 0.5-2: 0.5-2, preferred 1: 1.1: 1.2.
Described condensation and cyclization reaction catalyst system therefor is lewis acid catalyst, specifically can be the fluoroform sulphonate of aluminum chloride, zinc chloride, iron trichloride, boron trifluoride, columbium pentachloride or Indium-111 chloride or lanthanon, preferred aluminum chloride.
Described raw material 2, the preparation process of 4-two chloro-5-methoxybenzaldehydes (III) comprising: 3-methoxyl group benzylalcohol (IIIa) obtains 2 through chlorination reaction, 4-two chloro-5-methoxyl group benzylalcohols (IIIb), intermediate (IIIb) obtains 2,4-, two chloro-5-methoxybenzaldehydes (III) through oxidizing reaction.
The chlorizating agent of described chlorination reaction is chlorine, sulfuryl chloride, thionyl chloride, phosphorus trichloride or phosphorus pentachloride, preferred sulfuryl chloride.
The oxidizer system of described oxidizing reaction is activated manganese dioxide, pyridinium chlorochromate (PCC), chlorine dichromic acid pyridine (PDC), methyl-sulphoxide/oxalyl chloride (Swern), 2-iodoxy phenylformic acid (IBX), Dai Si-Martin's oxygenant (Dess-Martin Periodinane), sulphur trioxide/pyridine complex (Collins oxidation) or tetramethyl piperidine oxide compound (TEMPO), preferred activated manganese dioxide or pyridinium chlorochromate (PCC).
Than prior art, the preparation method of bosutinib involved in the present invention has that raw material is easy to get, technology is succinct and characteristics such as environmental protection and economy, so be beneficial to the suitability for industrialized production of this bulk drug, promotes the development of its economic technology.
Embodiment
Below in conjunction with several preferred embodiments technical solution of the present invention is done further nonrestrictive detailed description.
Embodiment one:
In three neck reaction flasks, add 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-amino-3-quinoline formonitrile HCN (II) (3.55g, 10mmol), triethylamine (1.5g, 15mmol) with methyl alcohol 25mL, be warming up to 50-55 ℃, be stirred to system dissolving homogeneous.(2.45g, methanol solution 12mmol) dripped off to reaction solution in about 1 hour slowly to drip 2,4-, two chloro-5-methoxybenzaldehydes (III).Keep this temperature to continue reaction 3 hours, the TLC detection reaction finishes.Be cooled to 0-5 ℃, add sodium borohydride (1.9g 50mmol), added in about 1 hour in batches.Keep room temperature to continue reaction 2 hours, the TLC detection reaction finishes.Add dilute hydrochloric acid cancellation reaction.Be evaporated to 1/3rd of cumulative volume, the cooling crystallization, crude product dehydrated alcohol recrystallization gets off-white color solid bosutinib (I) 4.2g, yield 79.4%.
Embodiment two:
Under dry and nitrogen atmosphere, in three mouthfuls of reaction flasks, add 3-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-anisidine (IIa) (2.8g, 10mmol), triethyl orthoformate (IIb) (1.63g, 11mmol) and the third two eyeball (IIc) (0.80g, 12mmol) with dehydrated alcohol 25mL, reflux 3 hours.Crystallisation by cooling, machine product N, after the dinethylformamide 25mL dissolving, (5.32g 40mmol), is heated to 140 ℃, insulation reaction 2 hours to add aluminum chloride.Cooling with reaction system impouring frozen water, has solid to separate out.Filter, filtrate is used dichloromethane extraction, concentrates, and the machine product obtain white solid 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-with ethyl alcohol recrystallization]-4-amino-3-quinoline formonitrile HCN (II) 3.1g, yield 87.3%.
Embodiment three:
(1.4g 10mmol) and acetic acid 25mL, is cooled to 0 ℃, stirs to drip sulfuryl chloride down (4.0g 30mmol), drips and finishes room temperature reaction 3 hours to add 3-methoxyl group benzylalcohol (IIIa) in three mouthfuls of reaction flasks.Be warming up to 70-80 ℃, continue reaction 0.5 hour, do not overflow to there being hydrogenchloride.Removal of solvent under reduced pressure, resistates obtains 2,4-, two chloro-5-methoxyl group benzylalcohols (IIIb) with ethyl alcohol recrystallization.The gained resistates dissolves with methylene dichloride 25mL, and adding pyridinium chlorochromate (PCC) (3.25g, 15mmol), room temperature reaction 2 hours.Add the 25mL anhydrous diethyl ether, continue reaction 2 hours.Filter, filter residue washs with ether, merges organic phase, removal of solvent under reduced pressure, and residuum gets light yellow solid 2 with re-crystallizing in ethyl acetate, 4-two chloro-5-methoxybenzaldehyde (III) 1.2g, yield is 58.8%.
It is pointed out that above-described embodiment only is explanation technical conceive of the present invention and characteristics, its purpose is to allow the personage who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalences that spirit is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (10)
1. the preparation method of a bosutinib (I),
It is characterized in that described preparation method, its preparation process comprises: 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-amino-3-quinoline formonitrile HCN (II) and 2,4-two chloro-5-methoxybenzaldehydes (III) carry out condensation, reduction reaction obtains bosutinib (I).
2. the preparation method of bosutinib (I) according to claim 1, it is characterized in that: the acid binding agent of described condensation reaction is salt of wormwood, saleratus, potassium hydroxide, yellow soda ash, sodium bicarbonate, sodium hydroxide, sodium methylate, potassium tert.-butoxide, triethylamine, diisopropylamine, pyridine, N-methylpyrrole, N-methyl piperidine or N-methylmorpholine.
3. the preparation method of bosutinib (I) according to claim 1, it is characterized in that: the reductive agent of described reduction reaction is sodium borohydride, POTASSIUM BOROHYDRIDE, sodium cyanoborohydride, acetoxyl group sodium borohydride or catalytic hydrogenation reaction.
4. as the preparation method of bosutinib (I) as described in the claim 3, it is characterized in that: described catalytic hydrogenation reaction is normal pressure hydrogenation, and catalyzer is palladium charcoal, palladium calcium carbonate or Raney's nickel.
5. the preparation method of bosutinib (I) according to claim 1 is characterized in that: described raw material 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-chemical structure of 4-amino-3-quinoline formonitrile HCN is suc as formula shown in (II),
6. as the preparation method of bosutinib (I) as described in the claim 5, it is characterized in that: described raw material 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-preparation process of 4-amino-3-quinoline formonitrile HCN (II) comprising: 3-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-anisidine (IIa), triethyl orthoformate (IIb) and the third two eyeballs (IIc) carry out the condensation and cyclization reaction and make described 6-methoxyl group-7-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-amino-3-quinoline formonitrile HCN (II).
7. as the preparation method of bosutinib (I) as described in the claim 6, it is characterized in that: the molar ratio of described condensation and cyclization reaction is 3-[3-(4-methyl isophthalic acid-piperazine) propoxy-]-4-anisidine (IIa): triethyl orthoformate (IIb): the third two eyeballs (IIc) are 1: 0.5-2: 0.5-2.
8. as the preparation method of bosutinib (I) as described in the claim 6, it is characterized in that: described condensation and cyclization reaction catalyst system therefor is the fluoroform sulphonate of aluminum chloride, zinc chloride, iron trichloride, boron trifluoride, columbium pentachloride or Indium-111 chloride or lanthanon.
9. the preparation method of bosutinib (I) according to claim 1, it is characterized in that: described raw material 2, the preparation process of 4-two chloro-5-methoxybenzaldehydes (III) comprising: 3-methoxyl group benzylalcohol (IIIa) obtains 2 through chlorination reaction, 4-two chloro-5-methoxyl group benzylalcohols (IIIb), described 2,4-two chloro-5-methoxyl group benzylalcohols (IIIb) obtain 2,4-, two chloro-5-methoxybenzaldehydes (III) through oxidizing reaction.
10. as the preparation method of bosutinib (I) as described in the claim 9, it is characterized in that: the oxidizer system of described oxidizing reaction is activated manganese dioxide, pyridinium chlorochromate, chlorine dichromic acid pyridine, methyl-sulphoxide/oxalyl chloride, 2-iodoxy phenylformic acid, Dai Si-Martin's oxygenant, sulphur trioxide/pyridine complex or tetramethyl piperidine oxide compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310236253 CN103265482A (en) | 2013-06-14 | 2013-06-14 | Preparation method of bosutinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310236253 CN103265482A (en) | 2013-06-14 | 2013-06-14 | Preparation method of bosutinib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103265482A true CN103265482A (en) | 2013-08-28 |
Family
ID=49009159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310236253 Pending CN103265482A (en) | 2013-06-14 | 2013-06-14 | Preparation method of bosutinib |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103265482A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123758A1 (en) * | 2014-02-20 | 2015-08-27 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
| CN104876865A (en) * | 2014-02-27 | 2015-09-02 | 南京正荣医药化学有限公司 | Preparation technology of bosutinib |
| WO2015198249A1 (en) * | 2014-06-27 | 2015-12-30 | Shilpa Medicare Limited | Process for preparation of bosutinib |
| CN105646345A (en) * | 2016-03-16 | 2016-06-08 | 浙江海正药业股份有限公司 | Novel crystal forms of bosutinib and preparation method thereof |
| CN109180578A (en) * | 2018-10-19 | 2019-01-11 | 山东创新药物研发有限公司 | A kind of preparation method of bosutinib |
-
2013
- 2013-06-14 CN CN 201310236253 patent/CN103265482A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015123758A1 (en) * | 2014-02-20 | 2015-08-27 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
| US9776970B2 (en) | 2014-02-20 | 2017-10-03 | Apotex Inc. | Bosutinib forms and preparation methods thereof |
| CN104876865A (en) * | 2014-02-27 | 2015-09-02 | 南京正荣医药化学有限公司 | Preparation technology of bosutinib |
| WO2015198249A1 (en) * | 2014-06-27 | 2015-12-30 | Shilpa Medicare Limited | Process for preparation of bosutinib |
| CN105646345A (en) * | 2016-03-16 | 2016-06-08 | 浙江海正药业股份有限公司 | Novel crystal forms of bosutinib and preparation method thereof |
| CN109180578A (en) * | 2018-10-19 | 2019-01-11 | 山东创新药物研发有限公司 | A kind of preparation method of bosutinib |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5832558B2 (en) | Process for producing benzo [b] thiophene compound | |
| CN106146379B (en) | A kind of synthetic method of Oxiracetam | |
| CN103265482A (en) | Preparation method of bosutinib | |
| BRPI0609496A2 (en) | process for the production of a compound, and benzothiophene dihydrobenzothiophene derivatives or salts thereof, and propionic acid ester | |
| CN114478690B (en) | Preparation method of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane derivative | |
| ES2629505T3 (en) | New method for synthesizing an intermediate of Rivaroxaban, 4- {4 - [(5S) -5- (aminomethyl) -2-oxo-1,3-oxazolidin-3-yl] phenyl]} morpholin-3-one | |
| CN110372598A (en) | A kind of new method synthesizing deuterated amide and deuterated sulfonamide | |
| CN101717359B (en) | Method for synthesizing indapamide | |
| AU2013250801A1 (en) | Process for the preparation of rivaroxaban and intermediates thereof | |
| CN106279104B (en) | A kind of process modification method preparing amber love song Ge Lieting | |
| CN109438448A (en) | A kind of indoles and compounds with 7-member cycle and its preparation method and application | |
| CN102964287B (en) | Synthesis method of 3-(4-chlorobutyl)-5-cyanoindole | |
| CN103288808A (en) | Preparation method of afatinib (I) | |
| CN105949153B (en) | synthesis method of tasimelteon | |
| TW200927738A (en) | Synthesis of quaternary salt compounds | |
| CN105198821A (en) | Preparation method of Rociletinib | |
| JP6904519B2 (en) | Manufacturing methods and intermediates for synthesizing intermediates for the antitumor drug niraparib | |
| CN103288804A (en) | Preparation method of nilotinib | |
| EP1440075A1 (en) | Novel 3beta-amino azabicyclooctane heteroaromatic amide derivatives, preparation method and therapeutic uses thereof | |
| CN103254183B (en) | Ah method is for the preparation method of Buddhist nun | |
| CN103265530A (en) | Preparation method of neratinib | |
| CN107722101A (en) | Steroidal pyridine derivatives and its preparation method and application | |
| CN105820102A (en) | Oxiracetam synthesis technology | |
| CN102942573A (en) | Preparation method of olanzapine | |
| CN103739606B (en) | The environmental protection synthetic method of 2-amino-5,8-two replacement [1,2,4] triazole [1,5-c] pyrimidine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130828 |